Skip to main content
 

Biosimilars Forum Makes Available Xcenda Study on Budgetary Impact of Biosimilars Coding

WASHINGTON, DC, July 19, 2017 - The Biosimilars Forum published the Xcenda study, "Estimating the Budgetary Impact of Biosimilar Coding Policies Under Medicare Part B," relating to CMS reimbursement of biosimilars (here). The Xcenda study demonstrates the need for changes in CMS reimbursement for Biosimilars under Medicare part B.

“With the approval of two biosimilars that share the same reference product, it is now more pressing than ever to address this reimbursement issue," said Stacie Phan, Biosimilars Forum President. "This study demonstrates the current CMS reimbursement policy for biosimilars needs to be addressed so that patients facing serious diseases and disorders can benefit from greater access to biosimilars,” Phan said.


About the Biosimilars Forum

The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

To learn more about biosimilars, the Forum, and how to get involved, visit BiosimilarsForum.org or go to @USbiosimilars to follow related conversations and join the dialogue.

Contact:
Aimee Steel Lubin
202.828.1895
aimee.lubin@hklaw.com
biosimilars@fkhealth.com

Date

Wednesday, July 19, 2017